Procter & Gamble Co vs Tilray Brands Inc — how do they compare? Procter & Gamble Co trades at $143.47 (market cap $338.13B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Procter & Gamble Co is far larger — about 571.6× Tilray Brands Inc's market cap, and Procter & Gamble Co pays a 2.99% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| PG | TLRY | |
|---|---|---|
Market Cap | $338.13B | $591.60M |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $21.00 |
52-Week Low | $138.10 | $3.88 |
Enterprise Value | $363.97B | $758.73M |
Dividend Yield | 2.99% | — |
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including a net income margin of 18.44% and ROE of 30.13%, though valuation ratios like P/E of 21.99 and P/S of 4.05 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.
PG offers stability with consistent dividend growth and solid cash flows, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical weakness suggests potential consolidation. Key risks include economic sensitivity and competitive pressures, while institutional activity shows mixed positioning.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →